Cargando…

PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma

BACKGROUND: Prenylated Rab acceptor 1 domain family, member 2 (PRAF2) is involved in the occurrence and progression of several malignant tumors. However, its potential role in esophageal squamous cell carcinoma (ESCC) is still unknown. METHODS: PRAF2 mRNA expression was determined in 77 frozen ESCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Zhaoye, Wei, Bin, Zhou, Yu, Wang, Qiuzi, Wang, Jiru, Sun, Yuan, Gao, Yong, Chen, Xiaofei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570937/
https://www.ncbi.nlm.nih.gov/pubmed/31200670
http://dx.doi.org/10.1186/s12885-019-5818-7
_version_ 1783427330801139712
author Qian, Zhaoye
Wei, Bin
Zhou, Yu
Wang, Qiuzi
Wang, Jiru
Sun, Yuan
Gao, Yong
Chen, Xiaofei
author_facet Qian, Zhaoye
Wei, Bin
Zhou, Yu
Wang, Qiuzi
Wang, Jiru
Sun, Yuan
Gao, Yong
Chen, Xiaofei
author_sort Qian, Zhaoye
collection PubMed
description BACKGROUND: Prenylated Rab acceptor 1 domain family, member 2 (PRAF2) is involved in the occurrence and progression of several malignant tumors. However, its potential role in esophageal squamous cell carcinoma (ESCC) is still unknown. METHODS: PRAF2 mRNA expression was determined in 77 frozen ESCC samples by quantitative reverse transcription-polymerase chain reaction (qPCR) and its association with clinical features and overall survival were evaluated. The roles of PRAF2 in ESCC cells were investigated by proliferation, cell cycle, invasion and apoptosis assays in vitro. RESULTS: The PRAF2 mRNA expression was significantly increased in ESCC tissues compared with matched surrounding non-tumor tissues. Survival analysis showed that high PRAF2 mRNA expression was associated with worse overall survival in ESCC patients. Multivariate analysis revealed that PRAF2 (hazard ratio 2.05, 95% CI 1.10–3.85, P = 0.025) emerged as the independent predictor for poor overall survival in ESCC. The in vitro experiments revealed that knockdown of PRAF2 expression blocked cell proliferation, cell cycle progression and cell invasion and induced cell apoptosis in ESCC cells. CONCLUSION: Taken together, our data demonstrate that PRAF2 could be used as a potential prognostic biomarker and represent a potential therapeutic target for ESCC.
format Online
Article
Text
id pubmed-6570937
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65709372019-06-20 PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma Qian, Zhaoye Wei, Bin Zhou, Yu Wang, Qiuzi Wang, Jiru Sun, Yuan Gao, Yong Chen, Xiaofei BMC Cancer Research Article BACKGROUND: Prenylated Rab acceptor 1 domain family, member 2 (PRAF2) is involved in the occurrence and progression of several malignant tumors. However, its potential role in esophageal squamous cell carcinoma (ESCC) is still unknown. METHODS: PRAF2 mRNA expression was determined in 77 frozen ESCC samples by quantitative reverse transcription-polymerase chain reaction (qPCR) and its association with clinical features and overall survival were evaluated. The roles of PRAF2 in ESCC cells were investigated by proliferation, cell cycle, invasion and apoptosis assays in vitro. RESULTS: The PRAF2 mRNA expression was significantly increased in ESCC tissues compared with matched surrounding non-tumor tissues. Survival analysis showed that high PRAF2 mRNA expression was associated with worse overall survival in ESCC patients. Multivariate analysis revealed that PRAF2 (hazard ratio 2.05, 95% CI 1.10–3.85, P = 0.025) emerged as the independent predictor for poor overall survival in ESCC. The in vitro experiments revealed that knockdown of PRAF2 expression blocked cell proliferation, cell cycle progression and cell invasion and induced cell apoptosis in ESCC cells. CONCLUSION: Taken together, our data demonstrate that PRAF2 could be used as a potential prognostic biomarker and represent a potential therapeutic target for ESCC. BioMed Central 2019-06-14 /pmc/articles/PMC6570937/ /pubmed/31200670 http://dx.doi.org/10.1186/s12885-019-5818-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Qian, Zhaoye
Wei, Bin
Zhou, Yu
Wang, Qiuzi
Wang, Jiru
Sun, Yuan
Gao, Yong
Chen, Xiaofei
PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
title PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
title_full PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
title_fullStr PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
title_full_unstemmed PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
title_short PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
title_sort praf2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570937/
https://www.ncbi.nlm.nih.gov/pubmed/31200670
http://dx.doi.org/10.1186/s12885-019-5818-7
work_keys_str_mv AT qianzhaoye praf2overexpressionpredictspoorprognosisandpromotestumorigenesisinesophagealsquamouscellcarcinoma
AT weibin praf2overexpressionpredictspoorprognosisandpromotestumorigenesisinesophagealsquamouscellcarcinoma
AT zhouyu praf2overexpressionpredictspoorprognosisandpromotestumorigenesisinesophagealsquamouscellcarcinoma
AT wangqiuzi praf2overexpressionpredictspoorprognosisandpromotestumorigenesisinesophagealsquamouscellcarcinoma
AT wangjiru praf2overexpressionpredictspoorprognosisandpromotestumorigenesisinesophagealsquamouscellcarcinoma
AT sunyuan praf2overexpressionpredictspoorprognosisandpromotestumorigenesisinesophagealsquamouscellcarcinoma
AT gaoyong praf2overexpressionpredictspoorprognosisandpromotestumorigenesisinesophagealsquamouscellcarcinoma
AT chenxiaofei praf2overexpressionpredictspoorprognosisandpromotestumorigenesisinesophagealsquamouscellcarcinoma